Breast Cancer Research and Treatment
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation.
201:257-264.
2023
-
Patient reported symptom burden amongst immigrant and Canadian long-term resident women undergoing breast cancer surgery.
199:553-563.
2023
-
A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles.
193:1-20.
2022
-
Axillary surgery and complication rates after mastectomy and reconstruction for breast cancer: an analysis of the NSQIP database.
192:501-508.
2022
-
Comparison of upper extremity lymphedema after sentinel lymph node biopsy and axillary lymph node dissection: patient-reported outcomes in 3044 patients.
191:87-96.
2022
-
Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study.
189:797-806.
2021
-
DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS.
188:133-139.
2021
-
Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers.
188:343-350.
2021
-
Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey.
187:477-486.
2021
-
Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers.
187:515-523.
2021
-
Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study.
187:759-768.
2021
-
A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients.
178:327-335.
2019
-
Multiple foci of microinvasion is associated with an increased risk of invasive local recurrence in women with ductal carcinoma in situ treated with breast-conserving surgery.
178:169-176.
2019
-
Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients.
178:347-356.
2019
-
The time-varying effect of radiotherapy after breast-conserving surgery for DCIS.
178:221-230.
2019
-
Patterns of adjuvant care and outcomes of elderly women with stage I breast cancer after breast-conserving surgery: a population-based analysis.
176:657-667.
2019
-
Body mass index impacts infection rates in immediate autogenous breast reconstruction.
175:765-773.
2019
-
Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
175:443-449.
2019
-
Patient-reported symptoms following mastectomy alone or lumpectomy plus radiation for early stage breast cancer: a cohort study.
175:721-731.
2019
-
Enhanced recovery after surgery (ERAS) pathways in breast reconstruction: systematic review and meta-analysis of the literature.
173:65-77.
2019
-
Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
173:455-463.
2019
-
Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study.
171:709-717.
2018
-
Effects of physical exercise after treatment of early breast cancer: systematic review and meta-analysis.
170:455-476.
2018
-
Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab.
170:169-177.
2018
-
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).
169:537-548.
2018
-
Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis.
168:299-310.
2018
-
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213..
167:485-493.
2018
-
Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival.
172:123-132.
2018
-
Does obesity modify the relationship between physical activity and breast cancer risk?.
166:367-381.
2017
-
Ablative Therapies in Metastatic Breast Cancer: A Systematic Review.
164:13-25.
2017
-
Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32.
164:371-378.
2017
-
Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
163:631-632.
2017
-
A single-institution experience of salvage therapy for patients with early and locally advanced breast cancer who progress during neoadjuvant chemotherapy.
163:11-19.
2017
-
Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
162:1-10.
2017
-
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.
161:117-134.
2017
-
A novel approach to breast cancer prevention: reducing excessive ovarian androgen production in elderly women.
158:553-561.
2016
-
Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies.
158:407-420.
2016
-
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.
157:109-116.
2016
-
Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.
157:101-108.
2016
-
Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
156:343-349.
2016
-
Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.
153:353-360.
2015
-
Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis.
151:639-652.
2015
-
Erratum to: Platinum-based chemotherapy in triple-negative advanced breast cancer.
150:697-697.
2015
-
Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer.
150:605-611.
2015
-
Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
149:439-448.
2015
-
Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications.
149:293-301.
2015
-
Tamoxifen-associated skin reactions in breast cancer patients: from case report to literature review.
148:1-5.
2014
-
Breast cancer and bone metastases: the association of axial skeleton MRI findings with skeletal-related events and survival.
146:583-589.
2014
-
Platinum-based chemotherapy in triple-negative advanced breast cancer.
146:567-572.
2014
-
Double heterozygosity for germline mutations in BRCA1 and p53 in a woman with early onset breast cancer.
146:447-450.
2014
-
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
146:421-427.
2014
-
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.
146:153-162.
2014
-
A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.
144:615-624.
2014
-
Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials.
142:143-151.
2013
-
Impact of primary local treatment on the development of distant metastases or death through locoregional recurrence in young breast cancer patients.
140:577-585.
2013
-
Clinical–pathologic significance of cancer stem cell marker expression in familial breast cancers.
140:195-205.
2013
-
Erratum to: Which nomogram is best for predicting non-sentinel lymph node metastasis in breast cancer patients? A meta-analysis.
139:295-300.
2013
-
Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis.
138:581-590.
2013
-
Fasting blood glucose and long-term prognosis of non-metastatic breast cancer: a cohort study.
138:951-959.
2013
-
Which nomogram is best for predicting non-sentinel lymph node metastasis in breast cancer patients? A meta-analysis.
137:783-795.
2013
-
A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer.
136:143-151.
2012
-
Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6.
136:117-127.
2012
-
TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.
132:225-234.
2012
-
Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial.
131:541-551.
2012
-
Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial.
130:133-143.
2011
-
Role of CD200 expression in regulation of metastasis of EMT6 tumor cells in mice.
130:49-60.
2011
-
Amplification of the prolactin receptor gene in mammary lobular neoplasia.
128:31-40.
2011
-
Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.
128:401-409.
2011
-
EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.
127:831-839.
2011
-
Estrogen receptor: is it predictive for response to cytotoxic as well as hormonal therapy?.
127:587-588.
2011
-
Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.
126:295-310.
2011
-
Erratum to: Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.
126:269-269.
2011
-
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents.
126:215-220.
2011
-
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).
123:453-461.
2010
-
High levels of uPA and PAI-1 predict a good response to anthracyclines.
121:625-626.
2010
-
Severe prolonged cholestatic hepatitis caused by exemestane.
121:789-791.
2010
-
Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients.
119:347-356.
2010
-
Prognosis of BRCA-associated breast cancer: a summary of evidence.
119:13-24.
2010
-
Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.
117:183-191.
2009
-
Is red meat intake a risk factor for breast cancer among premenopausal women?.
117:1-8.
2009
-
High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome.
114:517-525.
2009
-
Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?.
114:387-389.
2009
-
Lymphedema in women with breast cancer: characteristics of patients screened for a randomized trial.
110:337-342.
2008
-
HER2/neu in systemic therapy for women with breast cancer: a systematic review.
109:209-229.
2008
-
A Phase 2 study of perifosine in advanced or metastatic breast cancer.
108:87-92.
2008
-
Quality of Life Analyses in a Clinical Trial of DPPE (tesmilifene) Plus Doxorubicin Versus Doxorubicin in Patients with Advanced or Metastatic Breast Cancer: NCIC CTG Trial MA.19.
100:263-271.
2006
-
Dietary lignan intakes and risk of breast cancer by tumor estrogen receptor status.
99:309-311.
2006
-
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
99:295-300.
2006
-
Serum Lipids and Outcome of Early-stage Breast Cancer: Results of a Prospective Cohort Study.
94:135-144.
2005
-
PEA3, AP-1, and a unique repetitive sequence all are involved in transcriptional regulation of the breast cancer-associated gene, mammaglobin.
89:289-296.
2005
-
Locally advanced breast cancer in octogenarian women.
89:81-90.
2005
-
Prognostic factors affecting the natural history of node-negative breast cancer.
89:35-45.
2005
-
Is expert breast pathology assessment necessary for the management of ductal carcinoma in situ?.
87:265-272.
2004
-
Hormone Replacement Therapy after Treatment for Breast Cancer: Physicians' Attitudes towards Randomized Trials.
79:213-223.
2003
-
Estradiol Promotes Growth and Angiogenesis in Polyoma Middle T Transgenic Mouse Mammary Tumor Explants.
78:1-6.
2003
-
A Comparison of Risk Perception and Psychological Morbidity in Women with Ductal Carcinoma in situ and Early Invasive Breast Cancer.
77:285-293.
2003
-
Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes.
74:65-76.
2002
-
Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer.
73:161-175.
2002
-
Expression of Ets-related Transcription Factors and Matrix Metalloproteinase Genes in Human Breast Cancer Cells.
72:227-232.
2002
-
Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter.
61:111-119.
2000
-
Multidisciplinary weight management in locoregional breast cancer: results of a phase II study.
48:53-64.
1998
-
A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1.
44:211-215.
1997
-
An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer.
44:201-210.
1997
-
Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue.
40:171-178.
1996
-
Droloxifene, a new antiestrogen: Its role in metastatic breast cancer.
31:83-94.
1994
-
Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer.
30:179-195.
1994
-
A comparison of all-subset Cox and accelerated failure time models with Cox step-wise regression for node-positive breast cancer.
22:263-272.
1992
-
The efficacy of bone scanning in the follow-up of patients with operable breast cancer.
4:303-307.
1984
-
Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32)
2023
-
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100)
2008
-
A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in elderly breast cancer patients
2007
-
Galactose oxidase Schiff's reactivity is higher in nipple aspirate fluid from cancerous breasts than from healthy patients
2007
-
How compliant are patients with oral hormonal therapies? Data from a randomized, placebo controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (NCIC CTG MA.12)
2007
-
Long-term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node negative breast cancer
2007
-
Natural history of skeletal complications in patients receiving chemotherapy for breast cancer metastatic to bone
2007
-
Patients' disease and treatment parameters significantly affect survival in metastatic breast cancer
2007
-
Survival in breast cancer patients with bone metastases and reductions in markers of bone resorption during zoledronic acid treatment.
2007
-
A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCICCTG MA. 21: Results of an interim analysis
2007
-
A phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy
2006
-
Canadian clinical practice patterns survey of adjuvant therapies for breast cancer.
2006
-
Cognitive impairment associated with chemotherapy for breast cancer: A mechanistic cohort study.
2006
-
Correlation between 2 or 3 year (y) disease-free survival (DFS) and 5y overall survival (OS) in adjuvant systemic trials of early stage breast cancer.
2006
-
Evaluating the performance of risk assessment models in BRCA1 and BRCA2 mutation detection.
2006
-
Metformin lowers fasting insulin levels in nondiabetic hyperinsulinemic early stage breast cancer (BC) patients - results of a phase II study.
2006
-
The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age.
2006
-
Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5).
2006
-
Baseline radiological staging in primary breast cancer: impact of an educational intervention on adherence to published guidelines.
2005
-
Meta-analysis examining the efficacy of serotonin selective reuptake inhibitors in the treatment of women with hot flashes
2005
-
Normalization of urinary N-telopeptide levels by zoledronic acid correlates with improved survival in patients with bone metastases from breast cancer.
2005
-
Complementary and alternative medicine use among patients with locally advanced breast cancer
2004
-
Effect of letrozole versus placebo on bone mineral density in women completing >= 5 years (yrs) of adjuvant tamoxifen: ncic ctg ma.17b
2004
-
Estimate of prognosis for node negative breast cancer patients is affected by survival analysis model.
2004
-
Phase II study of perifosine in metastatic or advanced breast cancer.
2004
-
Virtual wedge and intensity modulated radiotherapy reduce the magnitude of scattered radiation during adjuvant breast radiation.
2004
-
HER2 status: A Canadian experience of concordance between central and local testing laboratories
2003
-
Male breast cancer: why is the incidence increasing?
2003
-
Ten-year outcome of breast-conserving surgery (BCS) and radiotherapy (RT) in women with breast cancer (BC) and germline BRCA 1/2 mutations: results from an international collaboration
2003
-
The impact of having relatives affected with breast cancer on psychological distress in women at increased risk for breast cancer (BC)
2003
-
Tissue microarrays: accurate assessment of protein and DNA targets requires 3 cores per tumor sample.
2003
-
Urgent genetic assessment (GA) in the management of newly diagnosed familial breast cancer (br ca) patients: a feasibility study
2003
-
A prospective comparison of positron emission tomography scanning, sentinel lymph node biopsy and axillary dissection in staging patients with early stage breast cancer.
2002
-
A randomized trial comparing CEF to CME in premenopausal women with node positive breast cancer: update of NCICCTG MA.5.
2002
-
Feasibility and responsiveness of utility measurement in breast cancer patients: a prospective study.
2002
-
Health related quality of life (HRQOL) and psychosocial status at diagnosis are not associated with disease-free or overall survival (DFS or OS) in T1-3, N0-1, M0 breast cancer (BC).
2002
-
NAT2 interactions on breast cancer risk: SULT1A1 and cooked meat.
2002
-
Zoledronic acid (4mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90mg) in patients with breast cancer and bone metastasis.
2002
-
Risk of acute leukemia following adjuvant epirubicin-based adjuvant chemotherapy for breast cancer.
2001
-
Mechanisms involved in the metastasis of cancer to bone
1993
-
A RANDOMIZED TRIAL COMPARING 12 WEEKS WITH 36 WEEKS OF ADJUVANT CHEMOTHERAPY IN STAGE-II BREAST-CANCER
1988
-
HER-2/NEU ONCOGENE AS A PROGNOSTIC FACTOR IN NODE NEGATIVE BREAST-CANCER
1988
-
THE INFLUENCE OF EXOGENOUS HORMONES ON ESTROGEN AND PROGESTERONE RECEPTORS IN PRIMARY BREAST-CARCINOMA
1988
-
A DOUBLE ANTIBODY-RADIOIMMUNOASSAY (RIA) FOR MONITORING METASTATIC BREAST-CANCER
1987
-
CANCER-CHEMOTHERAPY AND THROMBOSIS
1987
-
ENDOCRINE ACTIONS OF TAMOXIFEN THERAPY IN PREMENOPAUSAL PATIENTS WITH BREAST-CANCER
1987
-
RADIOIMMUNOLOCALIZATION STUDIES IN PATIENTS WITH METASTATIC BREAST-CANCER USING INDIUM-111-LABELED MA5 MOUSE MONOCLONAL-ANTIBODIES DIRECTED AT THE EPITHELIAL MEMBRANE ANTIGEN COMPLEX (EMAC)
1987
-
IDENTIFICATION OF ANTIGENIC DETERMINANTS RECOGNIZED BY A MONOCLONAL-ANTIBODY PANEL PREPARED VERSUS BREAST-TUMOR MEMBRANES
1986
-
PHASE-I-II STUDY OF FLUTAMIDE IN METASTATIC BREAST-CANCER
1986
-
QUALITY-OF-LIFE IN STAGE-II BREAST-CANCER - AN INSTRUMENT FOR CLINICAL-TRIALS
1986
-
PROGNOSTIC FACTORS (PF) IN POSTMENOPAUSAL WOMEN WITH AXILLARY NODE POSITIVE BREAST-CANCER (AN+)
1985
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)